ZA200103527B - Dispersible compositions containing L-DOPA ethyl ester. - Google Patents

Dispersible compositions containing L-DOPA ethyl ester. Download PDF

Info

Publication number
ZA200103527B
ZA200103527B ZA200103527A ZA200103527A ZA200103527B ZA 200103527 B ZA200103527 B ZA 200103527B ZA 200103527 A ZA200103527 A ZA 200103527A ZA 200103527 A ZA200103527 A ZA 200103527A ZA 200103527 B ZA200103527 B ZA 200103527B
Authority
ZA
South Africa
Prior art keywords
amount
moisture content
starch
weight
microcrystalline cellulose
Prior art date
Application number
ZA200103527A
Other languages
English (en)
Inventor
Galit Levin
Omer Tsipori
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of ZA200103527B publication Critical patent/ZA200103527B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200103527A 1998-11-10 2001-05-02 Dispersible compositions containing L-DOPA ethyl ester. ZA200103527B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10789398P 1998-11-10 1998-11-10

Publications (1)

Publication Number Publication Date
ZA200103527B true ZA200103527B (en) 2002-05-09

Family

ID=22319025

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200103527A ZA200103527B (en) 1998-11-10 2001-05-02 Dispersible compositions containing L-DOPA ethyl ester.

Country Status (13)

Country Link
US (2) US6376545B1 (no)
EP (1) EP1135118A1 (no)
JP (1) JP2002529407A (no)
CN (1) CN1329487A (no)
AU (1) AU764742B2 (no)
CA (1) CA2350304A1 (no)
HK (1) HK1041441A1 (no)
HU (1) HUP0104586A3 (no)
IL (1) IL143071A0 (no)
NO (1) NO20012265L (no)
NZ (1) NZ512027A (no)
WO (1) WO2000027385A1 (no)
ZA (1) ZA200103527B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376545B1 (en) 1998-11-10 2002-04-23 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing L-DOPA ethyl ester
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
WO2003041646A2 (en) 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
AU2004270174B2 (en) * 2003-08-29 2010-05-20 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
WO2005105035A2 (en) * 2004-04-29 2005-11-10 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Targeted nanoparticles for drug delivery
WO2006035414A2 (en) * 2004-09-30 2006-04-06 Ranbaxy Laboratories Limited Carbidopa and levodopa dispersible tablets
US20070003621A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
ES2383768T3 (es) * 2006-06-28 2012-06-26 Chelsea Therapeutics Inc. Composiciones farmacéuticas que comprenden droxidopa
CA2673511A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
JP2010520885A (ja) * 2007-03-09 2010-06-17 チェルシー・セラピューティクス,インコーポレイテッド 線維筋痛症の治療のためのドロキシドパ及びその医薬組成物
WO2008137923A2 (en) * 2007-05-07 2008-11-13 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
ES2615511T3 (es) 2009-05-19 2017-06-07 Celgene Corporation Formulaciones de 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolin-1,3-diona
US20130017274A1 (en) * 2011-03-16 2013-01-17 Buck Institute For Research On Aging Low dose lithium in the treatment or prophylaxis of parkinson's disease
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状(姿勢反射異常)の治療剤
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP6622310B2 (ja) * 2014-09-04 2019-12-18 ロブソル・ファーマシューティカルズ・アクチボラグLobsor Pharmaceuticals Aktiebolag レボドパ、ドーパミン脱炭酸酵素阻害薬およびcomt阻害薬を含む医薬組成物ならびにその投与方法
WO2016179540A1 (en) 2015-05-06 2016-11-10 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
RU2697411C2 (ru) * 2017-10-11 2019-08-14 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Композиция для лечения болезни Паркинсона
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716958B (en) 1970-10-30 1973-01-31 Hoffmann La Roche Phenylalanine amides
US3803120A (en) 1971-09-28 1974-04-09 Hoffmann La Roche Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
DE2246013A1 (de) 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
US3939253A (en) 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en) 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en) 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en) 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4771073A (en) 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4663349A (en) 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
ES2042520T3 (es) 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
EP0522128B1 (en) 1991-01-30 1996-01-17 The Wellcome Foundation Limited Water-dispersible tablets
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
US6376545B1 (en) 1998-11-10 2002-04-23 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing L-DOPA ethyl ester

Also Published As

Publication number Publication date
HUP0104586A2 (en) 2002-06-29
AU1716800A (en) 2000-05-29
NZ512027A (en) 2004-04-30
EP1135118A1 (en) 2001-09-26
US20020151589A1 (en) 2002-10-17
US6703424B2 (en) 2004-03-09
JP2002529407A (ja) 2002-09-10
NO20012265L (no) 2001-07-03
US6376545B1 (en) 2002-04-23
AU764742B2 (en) 2003-08-28
CN1329487A (zh) 2002-01-02
WO2000027385A1 (en) 2000-05-18
IL143071A0 (en) 2002-04-21
CA2350304A1 (en) 2000-05-18
HK1041441A1 (zh) 2002-07-12
NO20012265D0 (no) 2001-05-08
HUP0104586A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
US6703424B2 (en) Dispersible compositions containing L-DOPA ethyl ester
KR910004572B1 (ko) 경구용 당뇨병 치료제 제형의 제조방법
US4837032A (en) Theophylline sustained release tablet
AU630536B2 (en) Pimobendan compositions
US20040048902A1 (en) Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
SK286035B6 (sk) Farmaceutická kompozícia obsahujúca dekarboetoxyloratadín, použitie dekarboetoxyloratadínu a farmaceutickej kompozície
SK4862002A3 (en) Extended release formulations of erythromycin derivatives
UA29513C2 (uk) Фармацевтична композиція, що включає (е)-3,5-дигідрокси-7-[4'-4''-фторфеніл-2'-циклопропілхінолін-3'-іл]-6- гептенову кислоту
US20220409575A1 (en) Dosage forms of rofecoxib and related methods
US20040029777A1 (en) Pharmaceutical preparation for taste masking
US4601895A (en) Delayed-action acetylsalicylic acid formulations for oral administration
WO2024114797A1 (zh) 一种含氧化氯吡格雷的固体制剂及其制备方法
US20070053975A1 (en) Ramipril formulation
US7687542B2 (en) Rapidly bioavailable tablet and capsule formulations of diclofenac
US6509035B1 (en) Oral preparation of coenzyme a useful for lowering blood lipid and a method producing for same
US20070269512A1 (en) Gastroretentive sustained release formulations
CA1165241A (en) Sustained release theophylline tablet having reduced bulk
JP5347432B2 (ja) クレマスチンフマル酸塩含有固形製剤及びクレマスチンフマル酸塩含有量の低下抑制方法
CN101480397A (zh) 一种头孢克肟口腔崩解片及其制备方法
JP2568783B2 (ja) 2−エトキシ安息香酸を含有する鎮痛解熱消炎剤
CN112137974B (zh) 一种罗红霉素分散片及其制备方法
JP2005517720A (ja) レボチロキシン組成物及び方法
KR20040005257A (ko) 방출제어형 약제학적 조성물
CN115804774A (zh) 一种噁拉戈利的药物组合物,包含其的药物制剂,及其应用
CN109675057A (zh) 一种含有链霉蛋白酶的固体制剂及其制备方法